US6685941B1
(en)
*
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
IL92382A
(en)
*
|
1988-11-23 |
1994-12-29 |
Univ Michigan |
Use of a ligand specific for CD28 in the manufacture of medicament
|
WO1991006319A1
(fr)
*
|
1989-10-27 |
1991-05-16 |
Arch Development Corporation |
Procedes et compositions de promotion de l'immunopotentialisation
|
US6406696B1
(en)
|
1989-10-27 |
2002-06-18 |
Tolerance Therapeutics, Inc. |
Methods of stimulating the immune system with anti-CD3 antibodies
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US6090914A
(en)
*
|
1991-06-27 |
2000-07-18 |
Bristol-Myers Squibb Company |
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US5770197A
(en)
*
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
US6472510B1
(en)
*
|
1992-02-14 |
2002-10-29 |
Bristol-Myers Squibb Company |
CD40 receptor ligands
|
CA2089229C
(fr)
*
|
1992-02-14 |
2010-04-13 |
Alejandro A. Aruffo |
Recepteur cd40cr et ligands pour celui-ci
|
EP1488805A2
(fr)
*
|
1992-04-07 |
2004-12-22 |
The Regents of the University of Michigan |
Voie d'immunorégulation par CD28
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US5747034A
(en)
*
|
1992-07-09 |
1998-05-05 |
Chiron Corporation |
Methods and materials for the induction of T cell anergy
|
US5773253A
(en)
*
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
US6106834A
(en)
|
1993-06-02 |
2000-08-22 |
Research Corporation Technologies, Inc. |
Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
|
US6024957A
(en)
*
|
1993-06-02 |
2000-02-15 |
Research Corporation Technologies, Inc. |
Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
|
JPH08506247A
(ja)
*
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えctla4ポリペプチドおよびその製造方法
|
US20050129670A1
(en)
*
|
1993-07-26 |
2005-06-16 |
Genetics Institute, Llc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6824779B1
(en)
|
1993-07-26 |
2004-11-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting the interaction of B7-2 with its natural ligand
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
US6130316A
(en)
*
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
EP0711345A1
(fr)
|
1993-07-26 |
1996-05-15 |
Dana Farber Cancer Institute |
B7-2: contre-recepteur de ctl a4/cd 28
|
US5861310A
(en)
*
|
1993-11-03 |
1999-01-19 |
Dana-Farber Cancer Institute |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
US6723705B1
(en)
|
1993-08-19 |
2004-04-20 |
Gentics Institute, Inc. |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
WO1995005464A1
(fr)
*
|
1993-08-16 |
1995-02-23 |
Arch Development Corporation |
B7-2: contre recepteur de ctla4/cd28
|
WO1995006738A1
(fr)
*
|
1993-09-03 |
1995-03-09 |
Schering Corporation |
B70(b7-2):proteine de liaison de ctla-4
|
EP1025856A3
(fr)
*
|
1994-03-08 |
2002-10-16 |
Dana-Farber Cancer Institute |
Procédés de modulation de l'énergie des cellules T
|
AU784510B2
(en)
*
|
1994-03-08 |
2006-04-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating T cell unresponsiveness
|
US6719972B1
(en)
|
1994-06-03 |
2004-04-13 |
Repligen Corporation |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
|
US6083751A
(en)
*
|
1994-11-01 |
2000-07-04 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
|
CA2206610A1
(fr)
*
|
1994-12-02 |
1996-06-06 |
Schering Corporation |
Genes purifies codant des antigenes de surface de cellules mammaliennes; proteines et anticorps
|
US5576423A
(en)
|
1994-12-02 |
1996-11-19 |
Schering Corporation |
Antibodies to the slam protein expressed on activated T cells
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US5652224A
(en)
|
1995-02-24 |
1997-07-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US5872154A
(en)
*
|
1995-02-24 |
1999-02-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant adenovirus
|
WO1996031229A1
(fr)
*
|
1995-04-05 |
1996-10-10 |
Beth Israel Hospital Association |
Inhibition du rejet d'une greffe
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US5811097A
(en)
*
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5855887A
(en)
*
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US7041634B2
(en)
|
1995-09-27 |
2006-05-09 |
Emory University |
Method of inhibiting immune system destruction of transplanted viable cells
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
US6107056A
(en)
*
|
1996-02-22 |
2000-08-22 |
Oaks; Martin K. |
SCTLA-4 gene and product
|
ATE219376T1
(de)
*
|
1996-03-20 |
2002-07-15 |
Bristol Myers Squibb Co |
Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
|
US5786152A
(en)
*
|
1996-04-26 |
1998-07-28 |
Amgen Inc. |
Methods of inhibiting syp binding to a CTLA-4 receptor
|
EP1007090B1
(fr)
*
|
1996-11-08 |
2009-12-30 |
Biogen Idec Inc. |
IDENTIFICATION D'INTERACTIONS DE LIAISON UNIQUES ENTRE CERTAINS ANTICORPS ET LES ANTIGENES COSTIMULANTS B7.1 (CD80) ET B7.2 (cd28) HUMAINS
|
US20060034844A1
(en)
*
|
1996-12-04 |
2006-02-16 |
The Regents Of The University Of California |
Stimulation of T cells against self antigens using CTLA-4 blocking agents
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
KR19980066046A
(ko)
*
|
1997-01-18 |
1998-10-15 |
정용훈 |
고역가의 CTLA4-Ig 융합단백질
|
ZA98533B
(en)
*
|
1997-01-31 |
1999-07-22 |
Bristol Myers Squibb Co |
Soluble CTLA4 mutant molecules and uses thereof.
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
AU6703198A
(en)
|
1997-03-21 |
1998-10-20 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
SE9701127D0
(sv)
*
|
1997-03-26 |
1997-03-26 |
Karolinska Innovations Ab |
Antigenic fusionprotein carrying GALal, 3GAL epitopes
|
DE69840326D1
(de)
*
|
1997-03-27 |
2009-01-22 |
Csl Ltd |
Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
|
ATE505543T1
(de)
|
1997-04-16 |
2011-04-15 |
Millennium Pharm Inc |
Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
|
WO1998056401A1
(fr)
*
|
1997-06-12 |
1998-12-17 |
Applied Research Systems Ars Holding N.V. |
Peptidomimetiques inhibiteurs de cd28/ctla-4, compositions pharmaceutiques renfermant ceux-ci et procede d'utilisation de ceux-ci
|
WO1999015552A1
(fr)
*
|
1997-09-19 |
1999-04-01 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Composes oligopeptidiques
|
US7223729B2
(en)
*
|
1997-11-07 |
2007-05-29 |
Trillium Therapeutics Inc. |
Methods of treating allergy by administering a CD200 protein
|
US6955811B2
(en)
*
|
1997-11-07 |
2005-10-18 |
Trillium Therapeutics Inc. |
Methods of inhibiting immune response suppression by administering antibodies to OX-2
|
ATE319825T1
(de)
*
|
1997-11-07 |
2006-03-15 |
Trillium Therapeutics Inc |
Verfahren und zusammensetzungen zur immunomodulation
|
AUPP221098A0
(en)
*
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
ATE298248T1
(de)
*
|
1998-04-15 |
2005-07-15 |
Brigham & Womens Hospital |
T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
|
US7078512B2
(en)
|
1998-05-01 |
2006-07-18 |
Schering-Plough Animal Health Corporation |
Nucleic acid encoding feline CD86
|
US7279168B2
(en)
|
1998-05-01 |
2007-10-09 |
Texas A & M University System |
Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
|
US20050031611A1
(en)
*
|
1998-05-08 |
2005-02-10 |
Beth Israel Deaconess Medical Center |
Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
|
US6682741B1
(en)
*
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
AU775422B2
(en)
*
|
1998-06-15 |
2004-07-29 |
Gtc Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
US6593133B1
(en)
|
1998-07-06 |
2003-07-15 |
Nsgene A/S |
Neurotrophic factors
|
IL142069A0
(en)
|
1998-09-21 |
2002-03-10 |
Genetics Inst |
Methods of downmodulating the immune response to therapeutic proteins
|
US6800457B2
(en)
|
1998-09-22 |
2004-10-05 |
Bristol-Myers Squibb Company |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
US6521419B1
(en)
|
1998-09-22 |
2003-02-18 |
Kanakaraju Koduri |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
PT2112166T
(pt)
|
1998-12-23 |
2019-01-30 |
Pfizer |
Anticorpos monoclonais humanos contra ctla-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US7011833B1
(en)
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
AU6615500A
(en)
*
|
1999-07-28 |
2001-02-19 |
Genetics Institute Inc. |
Preventing immune-mediated abortion by inhibiting costimulation
|
KR100942863B1
(ko)
|
1999-08-24 |
2010-02-17 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
AU2926401A
(en)
*
|
2000-01-03 |
2001-07-16 |
Tr Associates, L.L.C. |
Novel chimeric proteins and methods for using the same
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
IL152315A
(en)
*
|
2000-05-26 |
2010-04-15 |
Bristol Myers Squibb Co |
Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
CN1438894A
(zh)
*
|
2000-06-09 |
2003-08-27 |
布里斯托尔-迈尔斯斯奎布公司 |
通过阻断淋巴细胞信号和阻断lfa-1介导的粘附作用调节细胞介导的免疫应答的方法
|
US20040034193A1
(en)
*
|
2001-06-13 |
2004-02-19 |
Samy Ashkar |
Biosynthetic oncolytic molecules and uses therefor
|
US20050048614A1
(en)
*
|
2000-06-13 |
2005-03-03 |
Children's Medical Center Corporation |
Biosynthetic oncolytic molecules and uses therefor
|
SK287940B6
(sk)
|
2000-07-03 |
2012-05-03 |
Bristol-Myers Squibb Company |
Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
US6875904B2
(en)
*
|
2000-09-20 |
2005-04-05 |
The Ohio State University Research Foundation |
Animal model for identifying agents that inhibit or enhance CTLA4 signaling
|
US7014998B2
(en)
*
|
2000-09-30 |
2006-03-21 |
Yale University |
Screening immunomodulatory agents by CTLA-4 upregulation
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
EP1341902A2
(fr)
*
|
2000-12-08 |
2003-09-10 |
Alexion Pharmaceuticals, Inc. |
Lignee cellulaire de la leucemie lymphoide chronique et son utilisation pour produire un anticorps
|
US7408041B2
(en)
*
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2004535364A
(ja)
*
|
2001-01-26 |
2004-11-25 |
エモリー・ユニバーシティ |
臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
JP4499362B2
(ja)
|
2001-03-28 |
2010-07-07 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
JP4837880B2
(ja)
|
2001-05-23 |
2011-12-14 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ctla4突然変異体分子を使って同種異系島移植片を保護する方法
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US20030086940A1
(en)
*
|
2001-08-10 |
2003-05-08 |
Cristina Costa |
Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
|
US20040116675A1
(en)
*
|
2001-12-14 |
2004-06-17 |
Tso J. Jun |
Silenced anti-cd28 antibodies and use thereof
|
US7858297B2
(en)
*
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
ATE451387T1
(de)
*
|
2001-12-18 |
2009-12-15 |
Endocube Sas |
Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
DE60329126D1
(de)
|
2002-02-20 |
2009-10-15 |
Beth Israel Hospital |
Konjugate mit biologisch abbaubarem polymer und verwendung dafür
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
AU2003234736B2
(en)
|
2002-04-12 |
2008-09-25 |
E. R. Squibb & Sons, L.L.C. |
Methods of treatment using CTLA-4 antibodies
|
WO2003092624A2
(fr)
*
|
2002-05-02 |
2003-11-13 |
University Of Connecticut Health Center |
Utilisation de proteines du stress en vue d'ameliorer l'efficacite de la therapeutique anticorps
|
US20040247578A1
(en)
*
|
2002-10-15 |
2004-12-09 |
University Of Pittsburgh Of Commonwealth System Of Higher Education |
Methods and reagents for inducing immunity
|
US7332303B2
(en)
*
|
2002-12-23 |
2008-02-19 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
CN101857851A
(zh)
*
|
2002-12-23 |
2010-10-13 |
布里斯托尔-迈尔斯斯奎布公司 |
用于蛋白质生产的哺乳动物细胞培养方法
|
RS52910B
(en)
|
2003-01-31 |
2014-02-28 |
Biogen Idec Ma Inc. |
POLYMER CONJUGATES OF MUTATED NEUBLASTINE
|
GB0303663D0
(en)
*
|
2003-02-18 |
2003-03-19 |
Lorantis Ltd |
Assays and medical treatments
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US6971600B2
(en)
*
|
2003-06-30 |
2005-12-06 |
Heligear Engineering (H.K.) Co., Ltd. |
Oscillation mechanism for fishing reel
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
RU2353384C2
(ru)
*
|
2003-08-04 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
|
EP1684791A4
(fr)
*
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
Compositions et procedes de modulation de la reaction immunitaire a un agent therapeutique immunogene
|
WO2006029219A2
(fr)
*
|
2004-09-08 |
2006-03-16 |
Ohio State University Research Foundation |
Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
|
EP1793857A4
(fr)
*
|
2004-09-08 |
2008-09-03 |
Univ Ohio State Res Found |
Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
|
GB0421465D0
(en)
*
|
2004-09-27 |
2004-10-27 |
Chiron Srl |
Group A streptococcus protein
|
NZ561655A
(en)
*
|
2005-04-06 |
2010-01-29 |
Bristol Myers Squibb Co |
Methods for treating immune disorders associated with graft transplantation with soluable CTLA4 mutant molecules
|
SG163615A1
(en)
|
2005-07-11 |
2010-08-30 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
EP1912675B1
(fr)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
|
JP4899083B2
(ja)
*
|
2005-08-29 |
2012-03-21 |
Smc株式会社 |
減速比自動切換装置
|
US20070111962A1
(en)
*
|
2005-11-08 |
2007-05-17 |
Mourich Dan V |
Immunosuppression compound and treatment method
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
AU2013202533B2
(en)
*
|
2005-11-08 |
2015-11-12 |
Sarepta Therapeutics, Inc. |
Immunosuppression Compound and Treatment Method
|
WO2007067959A2
(fr)
|
2005-12-07 |
2007-06-14 |
Medarex, Inc. |
Regimes d'escalade de dose d'anticorps ctla-4
|
KR101391457B1
(ko)
|
2005-12-20 |
2014-05-19 |
브리스톨-마이어스 스큅 컴퍼니 |
조성물 및 조성물의 제조 방법
|
SG10201400426XA
(en)
|
2006-01-12 |
2014-07-30 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
CA2646329C
(fr)
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Anticorps modifies diriges contre l'antigene de cellules souches prostatiques servant a cibler le cancer
|
US7528111B2
(en)
*
|
2006-05-12 |
2009-05-05 |
Bristol-Myers Squibb Company |
Method of vaccinating subjects receiving immune modulating therapy
|
US8409577B2
(en)
|
2006-06-12 |
2013-04-02 |
Emergent Product Development Seattle, Llc |
Single chain multivalent binding proteins with effector function
|
AU2007260687B2
(en)
|
2006-06-14 |
2013-12-12 |
Provention Bio, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
EP2185593B1
(fr)
*
|
2007-07-25 |
2017-12-13 |
Alexion Pharmaceuticals, Inc. |
Compositions pour traiter une maladie auto-immune
|
EP2197491A4
(fr)
|
2007-09-04 |
2011-01-12 |
Univ California |
Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
|
WO2009058564A2
(fr)
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Polypeptide immunosuppresseur et acides nucléiques
|
JP6013733B2
(ja)
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
US7915222B2
(en)
*
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
KR20170091801A
(ko)
|
2008-10-02 |
2017-08-09 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd86 길항제 다중-표적 결합 단백질
|
WO2010057047A1
(fr)
*
|
2008-11-13 |
2010-05-20 |
Trubion Pharmaceutics, Inc. |
Thérapies d’association immunothérapeutique cd37 et utilisations de celles-ci
|
US8840889B2
(en)
*
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
CA2777226A1
(fr)
|
2009-10-12 |
2011-04-21 |
Pfizer Inc. |
Traitement d'un cancer
|
KR20130049775A
(ko)
|
2010-03-12 |
2013-05-14 |
애브비 바이오테라퓨틱스 인크. |
Ctla4 단백질 및 이의 용도
|
WO2011123813A2
(fr)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
|
CA2812057A1
(fr)
|
2010-09-28 |
2012-04-05 |
Kahr Medical Ltd. |
Compositions et procedes de traitement de malignites hematologiques
|
WO2013010537A1
(fr)
|
2011-07-20 |
2013-01-24 |
Aarhus Universitet |
Procédé de traitement de la morphée
|
WO2013148049A1
(fr)
|
2012-03-29 |
2013-10-03 |
The General Hospital Corporation |
Protéine 4 associée aux lymphocytes t cytotoxiques (ctla4) recombinant
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
SG11201405968SA
(en)
|
2012-05-11 |
2014-11-27 |
Medimmune Llc |
Ctla-4 variants
|
US8735359B2
(en)
|
2012-05-24 |
2014-05-27 |
Orban Biotech Llc |
Combinations of modalities for the treatment of diabetes
|
CN104519900A
(zh)
|
2012-06-27 |
2015-04-15 |
欧尔本生物科技有限责任公司 |
用于治疗糖尿病的ctla4融合蛋白
|
US20140112958A1
(en)
|
2012-10-24 |
2014-04-24 |
Mwm Biomodels Gmbh |
Pancreatic islets of transgenic LEA29Y animals for treating diabetes
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
EP3757130A1
(fr)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Méthodes de traitement de cancers hématologiques
|
EP2883883A1
(fr)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Cibles thérapeutiques et agents utiles dans le traitement des lésions ischémiques de reperfusion
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
GB2523399B
(en)
|
2014-02-25 |
2019-03-13 |
Orban Tihamer |
A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
|
US20170281624A1
(en)
|
2014-09-13 |
2017-10-05 |
Novartis Ag |
Combination therapies of alk inhibitors
|
AU2015374385B2
(en)
|
2014-12-31 |
2020-08-06 |
Checkmate Pharmaceuticals, Inc. |
Combination tumor immunotherapy
|
EP3283508B1
(fr)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Protéines immunomodulatrices à affinités accordables
|
KR20180053322A
(ko)
|
2015-09-21 |
2018-05-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
EP3192805A1
(fr)
|
2016-01-15 |
2017-07-19 |
Humanitas Mirasole S.p.A. |
Inhibiteurs de l'activation ou la stimulation des lymphocytes t et leurs utilisations
|
WO2018160536A1
(fr)
|
2017-02-28 |
2018-09-07 |
Bristol-Myers Squibb Company |
Utilisation d'anticorps anti-ctla-4 avec adcc améliorée pour renforcer la réponse immunitaire d'un vaccin
|
WO2018187227A1
(fr)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Procédés de traitement du cancer à l'aide d'anticorps ciblant ps avec des agents immuno-oncologiques
|
WO2019067499A1
(fr)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200
|
KR20230020022A
(ko)
|
2017-10-10 |
2023-02-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
AU2019251421A1
(en)
|
2018-04-09 |
2020-10-29 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
EP3617230A1
(fr)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Nouvelles séquences d'anticorps et de nucléotides et utilisations associées
|
CA3120576A1
(fr)
|
2018-11-26 |
2020-06-04 |
Massachusetts Institute Of Technology |
Compositions et procedes pour induire une tolerance immunitaire
|
KR20220101167A
(ko)
|
2019-11-21 |
2022-07-19 |
브리스톨-마이어스 스큅 컴퍼니 |
무표지 n-글리칸 정량화 방법
|
WO2022178090A2
(fr)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Polypeptides de fusion dnase, compositions et méthodes associées
|
GB202115803D0
(en)
|
2021-11-03 |
2021-12-15 |
Ducentis Biotherapeutics Ltd |
Novel proteins
|
WO2023214388A1
(fr)
|
2022-05-06 |
2023-11-09 |
Ducentis Biotherapeutics Limited |
Nouvelles protéines de fusion cd200
|
WO2023214387A1
(fr)
|
2022-05-06 |
2023-11-09 |
Ducentis Biotherapeutics Limited |
Nouvelles protéines de fusion cd200
|
CN114686427B
(zh)
*
|
2022-05-23 |
2022-07-29 |
中国人民解放军总医院第一医学中心 |
一种脾脏调节型b淋巴细胞及其制备方法与应用
|